A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Mental health and substance abuse (MH/SA) comorbidities are the most oft-cited reasons for deferral from peginterferon (PegIFN) therapy for chronic hepatitis C virus (HCV). We sought to determine whether an integrated care intervention (INT) for patients deferred from PegIFN owing to MH/SA could improve subsequent treatment eligibility rates. METHODS: In this randomized controlled trial, 101 HCV patients who were evaluated at two hepatology centers and deferred from antiviral therapy owing to MH/SA were enrolled. Participants were randomized to an INT (N=50) or standard of care (SC; N=51). The INT group received counseling and case management for up to 9 months. All participants underwent 3-, 6-, and 9-month clinical follow-up visits, where hepatologists, masked to group, re-evaluated patients for treatment eligibility. Standardized mood and alcohol use instruments were administered to all participants to aid clinicians in treatment decisions. RESULTS: Of 101 participants, the mean age was 48 years and 50% were men, 61% Caucasian, and 77% genotype 1. Patients were initially deferred owing to psychiatric issues (35%), alcohol abuse (31%), drug abuse (9%), or more than one of these reasons (26%). In an intent-to-treat analysis, 42% (21/50) of INT participants became eligible for therapy compared to 18% (9/51) of SC participants (P=0.009, relative risk (RR)=2.38, 95% confidence interval (CI) (1.21, 4.68)). When baseline predictors significant at P<0.10 in univariate models were entered into multivariate models adjusted for treatment group, only baseline depression remained significant (P=0.05, RR=0.98, 95% CI (0.96, 1.00)). With the exception of a model adjusted for genotype, treatment group remained significant in all models. CONCLUSIONS: This trial suggests that INTs can increase eligibility for HCV treatment and expand treatment to the underserved population with MH/SA comorbidities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597 · cited 1×
“The Alcohol Use Disorders Identification Test assessed frequency and severity of alcohol use (42).”
MethodPrevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness
(2001) · American Journal of Public Health · doi:10.2105/ajph.91.1.31 · Cited by 589
Drake, R. E., O'Neal, E. L., & Wallach, M. A. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.01.011 · Cited by 447 · cited 1×
“For patients who were motivated to address their problems, case management strategies were primarily employed, such as identifying appropriate local MHsSA services and assisting with referral and follow-up with MHsSA providers (”
MethodBarrera, M., Glasgow, R. E., McKay, H. G., Boles, S. M., & Feil, E. G. (2002) · American Journal of Community Psychology · doi:10.1023/a:1016369114780 · Cited by 333
Klinkenberg, W. D., Caslyn, R. J., Morse, G. A., Yonker, R. D., McCudden, S., Ketema, F., & Constantine, N. T. (2003) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(03)00094-4 · Cited by 95
Psychiatric and Substance Use Disorders in Individuals with Hepatitis C: Epidemiology and Management
Loftis, J. M., Matthews, A. M., & Hauser, P. (2006) · Drugs · doi:10.2165/00003495-200666020-00003 · Cited by 86
Neri, S., Bertino, G., Petralia, A., Giancarlo, C., Rizzotto, A., Calvagno, G. S., Mauceri, B., Abate, G., Boemi, P., Di Pino, A., et al. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181d88af5 · Cited by 37 · cited 1×
“With the exception of one recent study (31), no randomized controlled trials (RCTs) have compared different models of care to standard care, and no study has explored the impact of such models on increasing access to care and improving treatment eligibility rates.”
Background
Cited by
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., Byrne, J., Dalgard, O., Feld, J. J., Hellard, M., et al. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.07.005 · Cited by 194
“Care coordination in conjunction with behavioral interventions increase the likelihood of being evaluated by a HCV specialist and initiating treatment (Evon et al., 2011; Masson et al., 2013).”
BackgroundZhou, K., Fitzpatrick, T., Walsh, N., Kim, J. Y., Chou, R., Lackey, M., Scott, J., Lo, Y.-R., & Tucker, J. D. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30208-0 · Cited by 167
Ho, S. B., Bräu, N., Cheung, R., Liu, L., Sanchez, C., Sklar, M., Phelps, T. E., Marcus, S. G., Wasil, M. M., Tisi, A., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.02.022 · Cited by 118
Bonner, J. E., Barritt, A. S., Fried, M. W., & Evon, D. M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2141-4 · Cited by 32
“In either integrated or collaborative/hybrid settings, patients may be more likely to overcome barriers, access treatment, initiate antiviral treatment, and have improved adherence to antiviral medication compared to those without such support [12, 30].”
InfluentialSelf-citation
Metadata
- Authors
- Evon, D. M., Simpson, K., Kixmiller, S., Galanko, J., Dougherty, K., Golin, C., & Fried, M. W.
- Venue
- American Journal of Gastroenterology
- Published
- 2011-10
- Volume
- 106
- Issue
- 10
- Pages
- 1777-1786
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W1968691835
- Cited by
- 70
- References
- 7
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment. https://app.cochat.ai/papers/10.1038/ajg.2011.219
- The paper
- Evon, D. M., Simpson, K., Kixmiller, S., Galanko, J., Dougherty, K., Golin, C., & Fried, M. W. (2011). A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2011.219
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.